← Leaderboards
Joerg Herrmann
Mayo Clinic Rochester
$2,909,034
Attributed
$5,067,629
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $967.2K · FY2014–24$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,067,629 · 2
By mechanism
R01$4,317,191 · 1
K08$750,438 · 1
Top collaborators
- Kathryn Jean Ruddy6 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Anne Josephine Novak$1,635,254
- Scott H Kaufmann$29,002,745
- Asish Kumar Ghosh$2,307,685
- Jyotishman Pathak$11,987,741
- Horng H Chen$12,297,202
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseCardiovascular Risk FactorInjuryGeneticMortalityBasePatient-Focused OutcomesCohortClinicDropsCaringCarvedilolClinical CareClinical TrialsCardiotoxicityAdrenergic Beta-AntagonistsCardioprotectionActive MethodBloodBreast Cancer PatientBreast Cancer TreatmentCardiacAdultCardiomyopathies
Grant awards (11)
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial$773,975
R01 · FY2024 · CA · contact PI
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial$798,417
R01 · FY2023 · CA · contact PI
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial$825,573
R01 · FY2022 · CA · contact PI
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial$1
R01 · FY2021 · CA · contact PI
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial$967,232
R01 · FY2020 · CA · contact PI
TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial$951,993
R01 · FY2019 · CA · contact PI
The pathophysiological role of the immunoproteasome in atherosclerosis$165,456
K08 · FY2018 · HL · contact PI
The pathophysiological role of the immunoproteasome in atherosclerosis$165,456
K08 · FY2017 · HL · contact PI
The pathophysiological role of the immunoproteasome in atherosclerosis$165,456
K08 · FY2016 · HL · contact PI
The pathophysiological role of the immunoproteasome in atherosclerosis$127,035
K08 · FY2015 · HL · contact PI
The pathophysiological role of the immunoproteasome in atherosclerosis$127,035
K08 · FY2014 · HL · contact PI